289 Results

People

  1. O'Reilly
    O'Reilly
  2. Abou-Alfa
    Abou-Alfa
  3. Motzer
    Motzer
  4. Drilon
    Drilon
  5. D'Angelica
    D'Angelica
  6. Horwitz
    Horwitz
  7. Jarnagin
    Jarnagin
  8. Moskowitz
    Moskowitz
  9. Panageas
    Panageas
  10. Aghajanian
    Aghajanian

Groups

  1. Department of Medicine (234)
  2. Solid Tumor Oncology Division (175)
  3. Hematologic Malignancies, Division of (77)
  4. Center for Hematologic Malignancies (63)
  5. Gastrointestinal Oncology Service (51)
  6. Epidemiology and Biostatistics (48)
  7. Center for Pancreatic Cancer Research (47)
  8. Biostatistics Service (46)
  9. GSK Faculty (42)
  10. Genitourinary Oncology Service (38)
  1. "aspartate aminotransferase"
Formats
  1. Journal Article (272)
  2. Review (11)
  3. Research Letter (4)
  4. Guidelines (2)
Groups
  1. Department of Medicine (234)
  2. Solid Tumor Oncology Division (175)
  3. Hematologic Malignancies, Division of (77)
  4. Center for Hematologic Malignancies (63)
  5. Gastrointestinal Oncology Service (51)
  6. Epidemiology and Biostatistics (48)

More Groups

People
  1. Eileen O'Reilly (15)
  2. Ghassan Abou-Alfa (12)
  3. Jedd Wolchok (12)
  4. Nancy Kemeny (12)
  5. Robert Motzer (12)
  6. Alexander Drilon (10)

More People

Years
  1. 2025 (18)
  2. 2024 (37)
  3. 2023 (28)
  4. 2022 (19)
  5. 2021 (9)
  6. 2020 (30)

More Years

Publications
  1. Journal of Clinical Oncology (26)
  2. Lancet Oncology (21)
  3. Cancer (11)
  4. Clinical Cancer Research (11)
  5. Blood (10)
  6. ESMO Open (7)

More Publications

Publishers
  1. Elsevier Inc. (36)
  2. Elsevier Science, Inc. (33)
  3. American Society of Clinical Oncology (28)
  4. Nature Publishing Group (19)
  5. Oxford University Press (18)
  6. Wiley Blackwell (18)

More Publishers

Results (289)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Targeting the intracellular immune checkpoint CISH with CRISPR-Cas9-edited T cells in patients with metastatic colorectal cancer: A first-in-human, single-centre, phase 1 trial
    Journal Article

    Lou, E.; Choudhry, M. S.; Starr, T. K.; Folsom, T. D.; Bell, J.; Rathmann, B.; DeFeo, A. P.; Kim, J.; Slipek, N.; Jin, Z.; more...
    Lancet Oncology (2025)

    Fulltext@MSK | Save
  • A phase I/II study of the safety and efficacy of telaglenastat (CB-839) in combination with nivolumab in patients with metastatic melanoma, renal cell carcinoma, and non-small-cell lung cancer
    Journal Article

    Gouda, M. A.; Voss, M. H.; Tawbi, H.; Gordon, M.; Tykodi, S. S.; Lam, E. T.; Vaishampayan, U.; Tannir, N. M.; Chaves, J.; Nikolinakos, P.; more...
    ESMO Open (2025)

    Fulltext@MSK | Save
  • Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: A randomized phase 3 trial
    Journal Article

    Kopetz, S.; Yoshino, T.; Van Cutsem, E.; Eng, C.; Kim, T. W.; Wasan, H. S.; Desai, J.; Ciardiello, F.; Yaeger, R.; Maughan, T. S.; more...
    Nature Medicine (2025)

    Fulltext@MSK | Save
  • Prediction of checkpoint inhibitor immunotherapy efficacy for cancer using routine blood tests and clinical data
    Journal Article

    Yoo, S. K.; Fitzgerald, C. W.; Cho, B. A.; Fitzgerald, B. G.; Han, C.; Koh, E. S.; Pandey, A.; Sfreddo, H.; Crowley, F.; Korostin, M. R.; more...
    Nature Medicine (2025)

    Fulltext@MSK | Save
  • Reducing clinical trial eligibility barriers for patients with MDS: An icMDS position statement
    Review

    Borate, U.; Pugh, K.; Waller, A.; Welkie, R. L.; Huang, Y.; Bewersdorf, J. P.; Stahl, M.; DeZern, A. E.; Platzbecker, U.; Sekeres, M. A.; more...
    Hematology-American Society of Hematology Education Program (2025)

    Fulltext@MSK | Save
  • Final results from the phase Ia/Ib study of the novel bromodomain and extra-terminal domain inhibitor, BI 894999, in patients with advanced solid tumors or diffuse large B-cell lymphoma
    Journal Article

    Lauer, U. M.; Awada, A.; Postel-Vinay, S.; Shapiro, G. I.; Thieblemont, C.; Piha-Paul, S. A.; Paik, P. K.; Shepard, D. R.; Docampo, L. I.; Galot, R.; more...
    ESMO Open (2025)

    Fulltext@MSK | Save
  • Selective intra-arterial mitomycin-C infusions for treatment-refractory colorectal liver metastases
    Journal Article

    Sotirchos, V. S.; Silk, M. T.; Camacho, J. C.; Schatoff, E. M.; Kunin, H. S.; Alexander, E. S.; Zhao, K.; Connell, L. C.; Sofocleous, C. T.; Kemeny, N. E.
    Journal of Gastrointestinal Oncology (2025)

    Fulltext@MSK | Save
  • (90)Y-Transarterial radioembolization combined with immune checkpoint inhibitors in hepatocellular carcinoma: A systematic review
    Review

    Hosseini Shabanan, S.; Shobeiri, P.; Behnoush, A. H.; Haghshomar, M.; Fowler, K. J.; Lewandowski, R. J.
    Journal of Gastrointestinal Cancer (2025)

    Fulltext@MSK | Save
  • A phase I, first-in-human trial of KO-947, an ERK1/2 inhibitor, in patients with advanced solid tumors
    Journal Article

    Schram, A. M.; Boni, V.; Adjei, A. A.; Olszanski, A. J.; Vieito, M.; Francis, J. H.; Kurman, M.; Ahsan, J. M.; Tomkinson, B.; Garralda, E.
    ESMO Open (2025)

    Fulltext@MSK | Save
  • A phase 1 study of the combination of BH3-mimetic, navitoclax, and mTORC1/2 inhibitor, vistusertib, in patients with advanced solid tumors
    Journal Article

    Scott, S. C.; Farago, A.; Lai, W. V.; Zahurak, M.; Rudek, M. A.; Murray, J.; Carducci, M. A.; Uziel, T.; Takebe, N.; Gore, S. D.; more...
    Cancer Chemotherapy and Pharmacology (2025)

    Fulltext@MSK | Save